Verastem (VSTM) Registration Filing summary

Company overview and business model

• Focuses on developing and commercializing medicines for RAS/MAPK pathway-driven cancers, with a marketed product (AVMAPKI FAKZYNJA CO-PACK) in the U.S. and a pipeline targeting key cancer signaling pathways, including RAF/MEK and FAK inhibition.

• Recently received FDA accelerated approval for AVMAPKI FAKZYNJA CO-PACK in KRAS mutant recurrent low grade serous ovarian cancer, with plans to seek regulatory approval in Europe and Japan.

• Holds orphan drug designations for avutometinib and defactinib in the U.S., EU, and Australia for various cancer indications.

Financial performance and metrics

• Raised approximately $75 million in gross proceeds from a private placement completed in April 2025, selling common stock and pre-funded warrants.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling stockholders, except for cash received upon exercise of pre-funded warrants.

• Any net proceeds from warrant exercises will fund the launch of avutometinib and defactinib in low-grade serous ovarian cancer, continued R&D, and general corporate purposes.